Janssen to Present Updated Results of JNJ-4528 in P-Ib/II CARTITUDE-1 Study for Multiple Myeloma at ASCO 2020

 Janssen to Present Updated Results of JNJ-4528 in P-Ib/II CARTITUDE-1 Study for Multiple Myeloma at ASCO 2020

Janssen to Present Updated Results of JNJ-4528 in P-Ib/II CARTITUDE-1 Study for Multiple Myeloma at ASCO

Shots:

  • The P-Ib/II CARTITUDE-1 study involves assessing JNJ-4528 in 29 heavily pretreated patients with r/r MM. The P-Ib results will be shared at ASCO
  • The P-Ib/II study results: 100% ORR with 97% good PR and 3% PR; patients achieving stringent CR @median of 11.5mos (86%), PFS at 9mos (86%); median time to first response was 1mos. and 81% patients achieved MRD negative disease status at 10-5 or 10-6
  • JNJ-4528 (LCAR-B38M) is CAR-T cell therapy with two BCMA-targeting single domain Abs and has received EMA’s PRIME designation in Apr’2019 and ODD in Feb’2020. Additionally, in 2017, Janssen collaborated with Legend Biotech to develop and commercialize JNJ-452 while in May’2018, Janssen initiated the P-Ib/II study to assess JNJ-4528, informed by the LEGEND-2 study results

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Janssen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post